Laboratories / 10.06.2026
Why Standard Lab Ranges May Miss Early Signs of Metabolic Dysfunction: Emerging Research on Preventive Health and Early Intervention
[caption id="attachment_74222" align="aligncenter" width="500"]
Image source: Envato[/caption]
A patient receives lab results from their doctor. The results are within normal ranges, and for many people, the conversation about their lab panel ends there. But normal on a standard lab report does not mean optimal, and the gap between those two things is where a significant amount of early metabolic dysfunction goes undetected.
Researchers and clinicians working in preventive and functional medicine have been examining how conventional reference ranges are constructed, what they actually measure, and whether they reliably catch early-stage dysfunction before it progresses to diagnosable disease. Practitioners in the field of lifestyle medicine frequently use this kind of deeper metabolic assessment as a foundation for early intervention, working with patients before markers reach the thresholds that trigger a clinical diagnosis.
Image source: Envato[/caption]
A patient receives lab results from their doctor. The results are within normal ranges, and for many people, the conversation about their lab panel ends there. But normal on a standard lab report does not mean optimal, and the gap between those two things is where a significant amount of early metabolic dysfunction goes undetected.
Researchers and clinicians working in preventive and functional medicine have been examining how conventional reference ranges are constructed, what they actually measure, and whether they reliably catch early-stage dysfunction before it progresses to diagnosable disease. Practitioners in the field of lifestyle medicine frequently use this kind of deeper metabolic assessment as a foundation for early intervention, working with patients before markers reach the thresholds that trigger a clinical diagnosis.
Dr. Sinha[/caption]
Pranay Sinha, MD
Research Fellow
Section of Infectious Diseases
Boston University School of Medicine
MedicalResearch.com: What is the background for this study?
Response: In the early days of the COVID-19 pandemic there were no evidence-based treatments for severely ill patients infected with this virus. We formed an interdisciplinary group of physicians from departments of adult and pediatric infectious diseases, rheumatology, and pulmonary/critical care as well as clinical pharmacy specialists. Given some promising data from China, we instituted treatment with off-label IL-6 receptor inhibitors (tocilizumab and sarilumab). The rationale was to mitigate the exuberant immune response observed in some patients infected with SARS-CoV-2 (also called cytokine storm or cytokine release syndrome).
Quite quickly, we started noticing that giving the drug to our sickest patients wasn’t eliciting dramatic improvement. We reasoned that by the time patients were severely ill and requiring ventilators, the damage to their lungs from the cytokine storm had already taken place. It was like closing the barn door after the horse had already bolted.
Dr. Bollag[/caption]
Wendy Bollag, PhD, FAHA
Professor of Physiology
VA Research Career Scientist
Augusta University, Georgia
MedicalResearch.com: What is the background for this study?
Response: We have previously shown that the lipid (fat) phosphatidylglycerol (PG) is able to inhibit rapidly growing keratinocytes (skin cells) and promote their maturation. We also found that PG can suppress skin inflammation.
Since the common skin disease psoriasis is characterized by inflammation and excessive growth and abnormal maturation of skin cells, we believed that PG might be useful as a treatment. However, the mechanism of its anti-inflammatory effect was unknown. PG in the lung has been found to inhibit inflammation induced by microbes or their components, which work by activating the innate immune system via binding to proteins called toll-like receptors (TLRs); however, psoriasis is not considered to be an infectious disease.
We hypothesized that PG would also inhibit inflammation induced by anti-microbial peptides that activate TLRs. Anti-microbial peptides, produced normally by the skin to protect against infection, are known to be excessively up-regulated in psoriatic skin. 






Dr. Schulert[/caption]
MedicalResearch.com Interview
Grant S Schulert MD, PhD
Clinical Fellow, Division of Rheumatology
Cincinnati Childrens Hospital
Medical Research: What is the background for this study? What are the main findings?
Dr. Schulert: Influenza infection causes millions of illnesses annually, but most of those are relatively mild. In a subset of cases, patients can become critically ill, even if they are relatively young and healthy. Several previous reports had observed in these critically ill patients features of a hyperinflammatory syndrome known as HLH (hemophagocytic lymphohistiocytosis) or MAS (macrophage activation syndrome). This hyperinflammation can be triggered by other infections as well as in a subtype of juvenile arthritis, but there is also a familial form occurring in early childhood with known genetic causes. Our questions with this study were
1) how often are features consistent with HLH/MAS seen in fatal H1N1 influenza infections and
2) do patients with fatal H1N1 infection have genetic mutations associated with HLH/MAS?
Our collaborator Paul Harms, MD, and his team at the Michigan Center for Translational Pathology, University of Michigan Medical School identified 16 cases of fatal H1N1 influenza infection. Based on their clinical features, between 41-88% of these patients could be categorized as having a hyperinflammatory HLH/MAS. We then used processed tissue samples from the patients for whole exome genetic sequencing, which reads the entire genetic code of every gene in a person. Five patients carried mutations in genes which cause HLH, and several others carried mutations in genes linked to MAS. This suggests that there may be genetic risk factors for developing fatal hyperinflammatory syndromes in H1N1 infection.
